Publikationen

Borwin bandelow

Wissenschaftliche Publikationen/Scientific Publications

Publications in Medline: 117

Total publications: 234

Hirsch factor (h-factor, ISI): 25

Most cited papers:

Bandelow B, Zohar J, Hollander E, et al (2008b): World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 9:248-312.

Bandelow B (1995): Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 10:73-81

Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005): Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-96.

———————————————————————————————————————————————————————

Bandelow B (1995): Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 10:73-81.

Bandelow B (1996a): Einschränkung der Lebensqualität durch Panikstörung und Agoraphobie. Göttingen.

Bandelow B (1996b): Seminar social phobias - Clinical aspects and diagnosis of social phobias. Nervenheilkunde 15:315-318.

Bandelow B (1997): Panik- und Agoraphobieskala (PAS). Göttingen/Bern/Toronto/Seattle: Hogrefe.

Bandelow B (1998a): Therapie mit Antidepressiva. In Fox J, Rüther E (eds), Handbuch der Arzneimitteltherapie. Band I: Psychopharmaka. Stuttgart: Thieme, pp 65-113.

Bandelow B (1998b): Therapie mit Neuroleptika. In Fox J, Rüther E (eds), Handbuch der Arzneimitteltherapie. Band I: Psychopharmaka. Stuttgart: Thieme, pp 115-169.

Bandelow B (1999): Panic and Agoraphobia Scale (PAS). Göttingen/Bern/Toronto/Seattle: Hogrefe & Huber Publishers.

Bandelow B (2000a): Die generalisierte Angststörung. Versicherungsmedizin 52:115-8.

Bandelow B (2000b): Spezielles zu den einzelnen Neuroleptika. In Möller HJ MW, Bandelow B. (ed), Neuroleptika. Stuttgart: Wissenschaftliche Verlagsgesellschaft, pp (in press).

Bandelow B (2001): Panik und Agoraphobie. Ursachen, Diagnose und Behandlung. Wien: Springer.

Bandelow B (2002a): [Behavior therapy and antidepressive drugs. What helps with anxiety?]. MMW Fortschr Med Suppl 2:60-2, 64-5.

Bandelow B (2002b): Generalisierte Angststörung - Medikamentöse Therapie. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp (im Druck).

Bandelow B (2002c): How long to treat anxiety disorders? European Neuropsychopharmacology 12:S159-S160.

Bandelow B (2002d): Panikstörung und Agoraphobie - Medikamentöse Behandlung. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp (im Druck).

Bandelow B (2002e): Quick sedation of the agitated patient with zyprexa velotab - Innovation in acute psychiatric care. Nervenheilkunde 21:75-76.

Bandelow B (2003a): Angst- und Panikerkrankungen. Bremen: Uni-Med.

Bandelow B (2003b): Epidemiology of Depression and Anxiety. In Kasper S, den Boer JA, Sitsen AJM (eds), Handbook on Depression and Anxiety. New York, N.Y.: M. Dekker, pp 49-68.

Bandelow B (2003c): Generalisierte Angststörung - Medikamentöse und psychotherapeutische Verfahren und Kombinationstherapie im Vergleich. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp 109-110.

Bandelow B (2003d): Panikstörung und Agoraphobie - Medikamentöse und psychotherapeutische Verfahren und Kombinationstherapie im Vergleich. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp 77-88.

Bandelow B (2003e): Soziale Phobie - Medikamentöse Therapie. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp 133-136.

Bandelow B (2003f): Soziale Phobie - Medikamentöse und psychotherapeutische Verfahren und Kombinationstherapie im Vergleich. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp 137-140.

Bandelow B (2004a): Das Angstbuch. 9. Aufl. Reinbek: Rowohlt.

Bandelow B (2004b): Sertraline and exposure therapy in social phobia. Br J Psychiatry 184:271; author reply 271-2.

Bandelow B (2005): Treatment of panic anxiety disorder: An update. European Psychiatry 20:S155-S155.

Bandelow B (2006a): Angst- und Panikerkrankungen, 2. Auflage. Bremen: Uni-Med.

Bandelow B (2006b): Celebrities - vom schwierigen Glück, berühmt zu sein. 2. Aufl. Reinbek: Rowohlt.

Bandelow B (2006c): Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr 11:21-8.

Bandelow B (2006d): Generalized anxiety disorder (GAD): the treatment implications of clinical heterogeneity. European Neuropsychopharmacology 16:S579-S579.

Bandelow B (2007a): Das Buch für Schüchterne. Reinbek: Rowohlt.

Bandelow B (2007b): Long term treatment of anxiety disorders. European Psychiatry 22:S73-S73.

Bandelow B (2007c): New therapy options for anxiety and compulsive disorder. Nervenarzt 78:510-510.

Bandelow B (2007d): Pharmacological treatment of anxiety disorders - is there a state of the art. European Psychiatry 22:S90-S90.

Bandelow B (2007e): Prevalence of pain in depression. International Journal of Psychiatry in Clinical Practice 11:307-307.

Bandelow B (2007f): Therapy of fear disorder. Nervenarzt 78:241-241.

Bandelow B (2007g): Treatment-resistant panic anxiety disorder. European Neuropsychopharmacology 17:S207-S208.

Bandelow B (2008a): Celebrities (Chinese edition). Beijing: SDX Joint Publishing Company.

Bandelow B (2008b): Das Angstbuch (koreanische Ausgabe). Seoul: Puriwa Ipari Publishing Co. .

Bandelow B (2008c): Gwiazdy. Gdansk: Gdanskie Wydawnictwo.

Bandelow B (2008d): The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr 13:37-46.

Bandelow B (2008e): Recent developments in pharmacotherapy of GAD. International Journal of Neuropsychopharmacology 11:319-319.

Bandelow B (2009a): Angst-, Panik- und Zwangsstörungen. In Ludwig WD (ed), Arzneiverordnungen, 22. Auflage. ISBN 978-3-87360-015-7 Medizinische Medien Informations GmbH, pp 395-405.

Bandelow B (2009b): Angststörungen. In Scharmer U (ed), Arzthandbuch - Wirtschaftliche und evidenzbasierte Arzneiverordnung für die Praxis. ISBN: 978-3-9809457-5-2. München: Urban & Vogel, pp 135-137.

Bandelow B (2009c): [Eccentric life, early death. Borderline personality in the spotlight (interview by Dr. med. Brigitte Moreano)]. MMW Fortschr Med 151:6.

Bandelow B (2010a): Angststörungen. In Amberger S, Roll SC (eds), Psychiatriepflege und Psychotherapie. Stuttgart: Thieme, pp 366-73.

Bandelow B (2010b): Wenn die Seele leidet. Reinbek: Rowohlt.

Bandelow B (2011): Embitterment syndrome: options for psychopharmacological management. In Linden M, Maercker A (eds), Embitterment - societal, psychological, and clinical perspectives. Wien: Springer, pp 187-96.

Bandelow B, Álvarez Tichauer G, Späth C, Broocks A, Hajak G, Bleich S, Rüther E (2001): Separation anxiety and actual separation experiences during childhood in patients with panic disorder. Can J Psychiatry 46:948-52.

Bandelow B, Amering M, Benkert O, Marks I, Nardi AE, Osterheider M, Tannock C, Tremper J, Versiani M (1996a): Cardio-respiratory and other symptom clusters in panic disorder. Anxiety 2:99-101.

Bandelow B, Andersen HF, Dolberg OT (2007a): Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety 24:53-61.

Bandelow B, Baldwin DS (2010): Pharmacotherapy for panic disorder. In Stein DJ, Hollander E, Rothbaum BO (eds), Textbook of Anxiety Disorders. Washington, D.C./London: American Psychiatric Publishing, pp 399-433.

Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ (2006a): What Is the Threshold for Symptomatic Response and Remission for Major Depressive Disorder, Panic Disorder, Social Anxiety Disorder, and Generalized Anxiety Disorder? J Clin Psychiatry 67:1428-1434.

Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, Clary CM (2004a): Sertraline Versus Paroxetine in the Treatment of Panic Disorder: An Acute, Double-Blind Noninferiority Comparison. J Clin Psychiatry 65:405-413.

Bandelow B, Bleich S, Kropp S (2000a): Handbuch Psychopharmaka. Göttingen: Hogrefe.

Bandelow B, Bleich S, Kropp S (2004b): Handbuch Psychopharmaka, 2. Auflage, 2. Auflage ed. Göttingen: Hogrefe.

Bandelow B, Bleich S, Kropp S (2012): Handbuch Psychopharmaka, 3., vollständig überarbeitete Aufl., 2. Auflage ed. Göttingen: Hogrefe.

Bandelow B, Bobes J, Ahokas A, Eggens I, Liu S, Brecher M (2007b): Poster: Results from a phase III study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder. International Journal of Psychiatry in Clinical Practice 11:314-315.

Bandelow B, Boerner RJ, Kasper S, Linden M, Volz HP, Wittchen HU, Moller HJ (2007c): Drug treatment of generalized anxiety disorder (GAD) - a consensus statement. Psychopharmakotherapie 14:136-+.

Bandelow B, Broocks A (2002): Evaluating the efficacy of psychological therapy. Verhaltenstherapie 12:205-215.

Bandelow B, Broocks A (2006): Generalisierte Angststörungen - Hypothesen zur Ätiologie In Bandelow B (ed), Angst- und Panikerkrankungen, 2. Auflage. Bremen: UNI-MED, pp 105-108.

Bandelow B, Broocks A, Hajak G (1995a): Die Behandlung von Angsterkrankungen mit Clomipramin - eine Analyse von Kasuistiken. TW Neurologie/Psychiatrie November:7-9.

Bandelow B, Broocks A, Pekrun G, George A, Meyer T, Pralle L, Bartmann U, Hillmer-Vogel U, Ruther E (2000b): The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. Pharmacopsychiatry 33:174-81.

Bandelow B, Broocks B (1997): Die medikamentöse Behandlung der sozialen Phobie. In Buchheim (ed), Psychotherapie und Psychopharmaka. Stuttgart/New York: Schattauer.

Bandelow B, Brunner E, Beinroth D, Pralle L, Broocks A, Hajak G, Ruther E (1999): Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. Eur Arch Psychiatry Clin Neurosci 249:21-7.

Bandelow B, Brunner E, Broocks A, Beinroth D, Hajak G, Pralle L, Ruther E (1998a): The use of the Panic and Agoraphobia Scale in a clinical trial. Psychiatry Res 77:43-9.

Bandelow B, Charimo Torrente A, Rüther E (2004c): The role of environmental factors in the etiology of social anxiety disorder. In Bandelow B, Stein DJ (eds), Social Anxiety Disorder. New York, N.Y.: Marcel Dekker, pp 131-142.

Bandelow B, Charimo Torrente A, Wedekind D, Broocks A, Hajak G, Rüther E (2004d): Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder. Eur Arch Psychiatry Clin Neurosci 254:397-405.

Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H (2010a): Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13:305-20.

Bandelow B, Degner D, Kreusch U, Ruther E (1995b): Myocarditis under therapy with clozapine. Schizophr Res 17:293-4.

Bandelow B, Engel K, Wedekind D (2009): [Evidence-based medicine in therapy of anxiety disorders]. MMW Fortschr Med 151:89-91.

Bandelow B, Fritze J, Rüther E (1998b): Increased mortality in schizophrenia and the possible influence of antipsychotic treatment. Int J Psychiatry Clin Pract 2(Suppl2):S49-S57.

Bandelow B, Grohmann R, Rüther E (2000c): Unerwünschte Begleitwirkungen der Neuroleptika und ihre Behandlung. In Möller HJ (ed), Therapie psychiatrischer Erkrankungen, 2 ed. Stuttgart: Thieme, pp 217-235.

Bandelow B, Gruber O, Falkai P (2008a): Kurzlehrbuch Psychiatrie. Heidelberg: Steinkopff Verlag.

Bandelow B, Hajak G, Holzrichter S, Kunert HJ, Ruther E (1995c): Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems. Int Clin Psychopharmacol 10:83-93.

Bandelow B, Haug TT (2004): Sertraline and exposure therapy in social phobia * Author's reply. Br J Psychiatry 184:271-272.

Bandelow B, Heise CA, Banaschewski T, Rothenberger A (2006b): Handbuch Psychopharmaka für das Kindes- und Jugendalter. Göttingen: Hogrefe.

Bandelow B, Kaiya H (2006): Drug treatment for panic disorder. International Congress Series 1287:288-292.

Bandelow B, Krause J, Wedekind D, Broocks A, Hajak G, Ruther E (2005a): Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls. Psychiatry Res 134:169-79.

Bandelow B, Lam R (2010): Escitalopram in clinical practice. ISBN 978 1 85873 439 2. London: Current Medicine Group.

Bandelow B, Linden M (2009): Angsterkrankungen - Panikstörung, soziale und generalisierte Angststörung. In Voderholzer U, Hohagen F, Kriegel U (eds), Therapie psychischer Erkrankungen: State of the Art 2009/2010. ISBN 978-3437249013. München: Elsevier, pp 223-242.

Bandelow B, Linden M (2010): Angsterkrankungen - Panikstörung, soziale und generalisierte Angststörung (ICD-10 F4). In Voderholzer U, Hohagen F (eds), Therapie psychiatrischer Erkrankungen, 5. Auflage. München: Elsevier, pp 193-208.

Bandelow B, Linden M (2011): Angsterkrankungen - Panikstörung, soziale und generalisierte Angststörung (ICD-10 F4). In Voderholzer U, Hohagen F (eds), Therapie psychiatrischer Erkrankungen, 6. Auflage. München: Elsevier, pp 193-208.

Bandelow B, Margraf J (1994a): Empfehlungen für die Verwendung von Messinstrumenten in der klinischen Angstforschung. Fortschr Neurol Psychiatr 62:361-5.

Bandelow B, Margraf J (1994b): [Recommendations for the use of measuring instruments in clinical anxiety research]. Fortschr Neurol Psychiatr 62:361-5.

Bandelow B, Muller P (1990): Paranoid-Hallucinatory Syndromes in Multiple-Sclerosis. Nervenheilkunde 9:18-21.

Bandelow B, Muller P, Frick U, Gaebel W, Linden M, Muller-Spahn F, Pietzcker A, Tegeler J (1992): Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Dusseldorf, Gottingen, Munich, Federal Republic of Germany. Eur Arch Psychiatry Clin Neurosci 241:291-5.

Bandelow B, Muller P, Gaebel W, Kopcke W, Linden M, Muller-Spahn F, Pietzcker A, Reischies FM, Tegeler J (1990): Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Dusseldorf, Gottingen, Munich. Eur Arch Psychiatry Clin Neurosci 240:113-20.

Bandelow B, Muller P, Ruther E (1991a): [30 years experience with haloperidol]. Fortschr Neurol Psychiatr 59:297-321.

Bandelow B, Müller P, Rüther E (1991b): 30 Jahre Erfahrung mit Haloperidol. Fortschr Neurol Psychiat 8:297-321.

Bandelow B, Röthemeyer M, Sievert K, Hajak G, Rüther E (1996b): Panic disorder - acceptance of the diagnostic entity and preferred treatment. Anxiety 1996:99-101.

Bandelow B, Ruther E (1997): Antipsychotic treatment: Recent developments and pharmacological principles. Psychopharmakotherapie 4:6-17.

Bandelow B, Rüther E (1988): Neuroleptika in der Behandlung schizoaffektiver Psychosen. In A M (ed), Schizoaffektive Psychosen. Berlin/ Heidelberg/ New York: Springer, pp 149-58.

Bandelow B, Rüther E (1991): Serotonin und Depression. In Beckmann H, Osterheider M (eds), Neurotransmitter und psychische Erkrankungen. Berlin: Springer, pp 149-158.

Bandelow B, Rüther E (1993): Besonderheiten der Psychopharmakotherapie bei psychischen Kranken mit körperlichen Erkrankungen. In Möller H-J (ed), Therapie psychiatischer Erkrankungen. Stuttgart: Enke.

Bandelow B, Rüther E (1997): Antipsychotische Behandlung: jüngste Weiterentwicklungen und pharmakologischen Grundlagen. Psychopharmakotherapie 4:6-17.

Bandelow B, Rüther E (1998a): Anwendung von Neuroleptika bei psychischen Störungen im Rahmen internistischer Erkrankungen. In Gaebel W. KA (ed), Neuroleptika bei nicht-psychotischen Störungen, Vol 166-174. Berlin/ Heidelberg/ New York: Springer.

Bandelow B, Rüther E (1998b): Unerwünschte Wirkungen der Neuroleptika - Extrapyramidalmotorische Wirkungen. In Bandelow B RE (ed), Therapie mit klassischen Neuroleptika - heute und morgen. Berlin/ Heidelberg/ New York: Springer.

Bandelow B, Rüther E (2000): Besonderheiten der Psychopharmaka-Therapie bei psychisch Kranken mit körperlichen Erkrankungen. In Möller HJ (ed), Therapie psychiatrischer Erkrankungen, 2 ed. Stuttgart: Thieme, pp 1176-1184.

Bandelow B, Rüther E (2004): Treatment-resistant panic disorder. CNS Spectr 9:725-39.

Bandelow B, Saleh K, Pauls J, Domschke K, Wedekind D, Falkai P (2010b): Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: A gender-specific effect? World J Biol Psychiatry 11:66-70.

Bandelow B, Schmahl C, Falkai P, Wedekind D (2010c): Borderline personality disorder: A dysregulation of the endogenous opioid system? Psychol Rev 117:623-36.

Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Rüther E (2007d): Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 8:175-87.

Bandelow B, Sengos G, Wedekind D, Huether G, Pilz J, Broocks A, Hajak G, Rüther E (1997): Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder [published erratum appears in Pharmacopsychiatry 1997 Nov;30(6):278]. Pharmacopsychiatry 30:113-7.

Bandelow B, Sievert K, Rothemeyer M, Hajak G, Broocks A, Ruther E (1995d): [Panic disorder and agoraphobia: what is effective?]. Fortschr Neurol Psychiatr 63:451-64.

Bandelow B, Sievert K, Rothemeyer M, Hajak G, Broocks A, Rüther E (1995e): Panikstörung und Agoraphobie: Was wirkt? Fortschr Neurol Psychiatr 63:451-64.

Bandelow B, Sievert K, Röthemeyer M, Hajak G, Broocks A, Rüther E (1996c): Panikstörung und Agoraphobie: Welche Behandlung erhalten die Patienten? Psychopharmakotherapie (accepted for publication).

Bandelow B, Sievert K, Rothemeyer M, Hajak G, Ruther E (1995f): What treatments do patients with panic disorder and agoraphobia get? Eur Arch Psychiatry Clin Neurosci 245:165-71.

Bandelow B, Sojka F, Broocks A, Hajak G, Bleich S, Rüther E (2006c): Panic disorder during pregnancy and postpartum period. Eur Psychiatry 21:495-500.

Bandelow B, Spath C, Tichauer GA, Broocks A, Hajak G, Ruther E (2002a): Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder. Compr Psychiatry 43:269-78.

Bandelow B, Stein DJ (2004a): Pharmacotherapy of social anxiety disorder. In Bandelow B, Stein DJ (eds), Social Anxiety Disorder. New York, N.Y.: Marcel Dekker, pp 267-298.

Bandelow B, Stein DJ (2004b): Social Anxiety Disorder. New York, N.Y.: Marcel Dekker.

Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS (2007e): Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 40:152-6.

Bandelow B, Wedekind D (2006): Angst - Neurobiologie. In Förstl H, Hautzinger M, Roth G (eds), Neurobiologie psychischer Störungen. Heidelberg: Springer, pp 483-522.

Bandelow B, Wedekind D, Leon T (2007f): Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 7:769-81.

Bandelow B, Wedekind D, Pauls J, Broocks A, Hajak G, Rüther E (2000d): Salivary cortisol in panic attacks. American Journal of Psychiatry 157:454-6.

Bandelow B, Wedekind D, Sandvoss V, Broocks A, Hajak G, Pauls J, Peter H, Rüther E (2000e): Diurnal variation of cortisol in panic disorder. Psychiatry Res 95:245-50.

Bandelow B, Wolff-Menzler C, Wedekind D, Rüther E (2006d): Patienten mit Angst- und Panikstörungen - Wie lange muss behandelt werden? MMW-Fortschr.Med. 148:31-34.

Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ (2002b): World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171-99.

Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ (2005b): Leitlinien der World Federation of Societies of Biological Psychiatry (WFSBP) für die medikamentöse Behandlung von Angst-, Zwangs- und posttraumatischen Belastungsstörungen. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

Bandelow B, Zohar J, Kasper S, Moller HJ (2008c): How to grade categories of evidence. World J Biol Psychiatry 9:242-247.

Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP (2003): WCA-recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectrums 8:53-61.

Ansorg R, Gunesch D, Bandelow B, Thomssen R (1977): [Differentiation and diagnostic significance of immunoglobulin classes of antibodies against cell wall antigens of yeast and mycelial phase of Candida albicans (author's transl)]. Mykosen 20:167-77.

Baldwin DS, Allgulander C, Altamura AC, et al (2010a): Manifesto for a European anxiety disorders research network. Eur Neuropsychopharmacol 20:426-32.

Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (2010b): Treatment of Generalized Anxiety Disorder in Routine Clinical Practice: An International Survey. Journal of Psychopharmacology 24:A71-A71.

Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (2011): An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry.

Baldwin DS, Stein DJ, Dolberg OT, Bandelow B (2007): How long should an initial treatment period be in anxiety disorders and in major depressive disorder? An exploration of the randomised clinical trial database for escitalopram. J Clin Psychiatry in press.

Baldwin DS, Stein DJ, Dolberg OT, Bandelow B (2009): How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 24:269-75.

Bleich S, Bandelow B, Javaheripour K, Muller A, Degner D, Wilhelm J, Havemann-Reinecke U, Sperling W, Ruther E, Kornhuber J (2003): Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism. Neurosci Lett 335:179-82.

Bleich S, Degner D, Bandelow B, von Ahsen N, Ruther E, Kornhuber J (2000): Plasma homocysteine is a predictor of alcohol withdrawal seizures. Neuroreport 11:2749-52.

Broocks A, Bandelow B (1999a): Drs. Broocks and Bandelow Reply. Am J Psychiatry 156:1129a-1130.

Broocks A, Bandelow B (1999b): Fetal alcohol exposure and adult psychiatric disorders - Dr. Broocks and Bandelow reply. American Journal of Psychiatry 156:1129-1130.

Broocks A, Bandelow B, George A, Jestrabeck C, Opitz M, Bartmann U, Gleiter CH, Meineke I, Roed IS, Ruther E, Hajak G (2000a): Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 15:153-61.

Broocks A, Bandelow B, George A, Roed IS (2001a): Increased psychobehavioral responsiveness to M-chlorophenylpiperazine (m-CPP) and ipsapirone (IPS) in patients with panic disorder (PDA). J Neurochem 78:81-81.

Broocks A, Bandelow B, Koch K, Bartmann U, Kinkelbur J, Schweiger U, Hohagen F, Hajak G (2002): Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder. Neuropsychopharmacology 27:270-8.

Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E (1998): Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 155:603-9.

Broocks A, Junghanns K, Thiel A, Gleiter CH, Bandelow B (2000b): Advances in the pharmacotherapy of depression by new antidepressants. Fortschritte Der Neurologie Psychiatrie 68:17-24.

Broocks A, Junghanns K, Thiel A, Gleiter CH, Bandelow B (2000c): [New antidepressive drugs in comparison with classical tricyclics. Mechanism of action and clinical evaluation]. Fortschr Neurol Psychiatr 68:17-24.

Broocks A, Meyer T, George A, Hillmer-Vogel U, Meyer D, Bandelow B, Hajak G, Bartmann U, Gleiter CH, Ruther E (1999a): Decreased neuroendocrine responses to meta-chlorophenylpiperazine (m-CPP) but normal responses to ipsapirone in marathon runners. Neuropsychopharmacology 20:150-61.

Broocks A, Meyer T, Gleiter CH, Hillmer-Vogel U, George A, Bartmann U, Bandelow B (2001b): Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects. Psychopharmacology (Berl) 155:234-41.

Broocks A, Meyer T, Opitz M, Bartmann U, Hillmer-Vogel U, George A, Pekrun G, Wedekind D, Ruther E, Bandelow B (2003): 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. Eur Neuropsychopharmacol 13:153-64.

Broocks A, Meyer TF, Bandelow B, George A, Bartmann U, Ruther E, Hillmer-Vogel U (1997a): Exercise avoidance and impaired endurance capacity in patients with panic disorder. Neuropsychobiology 36:182-7.

Broocks A, Meyer TF, George A, Pekrun G, Hillmer-Vogel U, Hajak G, Bandelow B, Ruther E (1997b): [Value of sports in treatment of psychiatric illness]. Psychother Psychosom Med Psychol 47:379-93.

Broocks A, Meyer TF, George A, Pekrun G, HillmerVogel U, Hajak G, Bandelow B, Ruther E (1997c): The role of exercise in the treatment of psychiatric disorders. Psychotherapie Psychosomatik Medizinische Psychologie 47:379-393.

Broocks A, Peters M, Bandelow B, Ruther E (1999b): Physical activity and affective diseases. Verhaltenstherapie 9:7-8.

Broocks A, Ruther E, Munzel U, Hajak G, Wedekind D, Bandelow B (2000d): Responsiveness of central serotonin receptors in panic disorder: Effects of clomipramine treatment and exercise. European Psychiatry 15:243S-243S.

Degner D, Bandelow B, Akkan R, Kropp S, Nietmann PD, Ruther E, Bleich S (2003): Relevance of therapeutic drug monitoring (TDM) in patients with quetiapine administration. Pharmacopsychiatry 36:219-219.

Degner D, Bleich S, Grohmann R, Bandelow B, Ruther E (2000): Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry 34:880.

Degner D, Fiege O, Bandelow B, Grohmann R, Ruther E (2005): Oculogyric crisis under aripiprazol in combination with fluoxetin. Psychopharmakotherapie 12:32-33.

Degner D, Knievel A, Müller P, Bandelow B, Schaefer E, Grohmann R, Rüther E (2004): Akute Agranulozytose nach langjähriger Clozapinbehandlung. Psychopharmakotherapie 11:98-100.

Doering S, Wedekind D, Pilz J, Bandelow B, Adler L, Huether G (2001): Cortisol in night-urine: Introduction of a research method in psychoneuroendocrinology. Zeitschrift Fur Psychosomatische Medizin Und Psychotherapie 47:42-57.

Domschke K, Hohoff C, Jacob C, Maier W, Fritze J, Bandelow B, Krakowitzky P, Kastner F, Rothermundt M, Arolt V, Deckert J (2008): Chromosome 4q31-34 panic disorder risk locus: association of neuropeptide Y Y5 receptor variants. Am J Med Genet B Neuropsychiatr Genet 147B:510-6.

Domschke K, Reif A, Weber H, et al (2011): Neuropeptide S receptor gene - converging evidence for a role in panic disorder. Mol Psychiatry 16:938-48.

Engel K, Bandelow B, Gruber O, Wedekind D (2009): Neuroimaging in anxiety disorders. J Neural Transm 116:703-16.

Erhardt A, Czibere L, Roeske D, et al (2011): TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry 16:647-63.

Erhardt A, Lucae S, Kern N, et al (2008): Association of polymorphisms in the angiotensin-converting enzyme gene with syndromal panic attacks. Mol Psychiatry 13:242-3.

Fritze J, Bandelow B (1998a): The QT-interval and the new, atypical neuroleptic sertindole. Psychopharmakotherapie 5:115-120.

Fritze J, Bandelow B (1998b): The QT interval and the atypical antipsychotic, sertindole. International Journal of Psychiatry in Clinical Practice 2:265-273.

Gade K, Haussinger C, Bandelow B (2009): Atypical anorexia in a male patient accompanied by strong obsessive-compulsive symptoms successfully treated with naltrexone. Pharmacopsychiatry 42:164-5.

Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, Okasha A, Swinson RP, Zohar J (2003): WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. Cns Spectrums 8:7-16.

Hajak G, Bandelow B (1992): Angst und Schlafstörungen. München: Medizin Verlag

Hajak G, Bandelow B (1994): Pharmacotherapy of Insomnia in General-Practice. Medizinische Welt 45:258-263.

Hajak G, Bandelow B (1996): [Coincidence of anxiety and sleep disorders. Overview and case reports]. Fortschr Neurol Psychiatr 64:26-40.

Hajak G, Bandelow B (1998): Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 13:157-67.

Hajak G, Bandelow B, Zulley J, Pittrow D (2002): "As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia--assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry 14:1-7.

Hajak G, Clarenbach P, Fischer W, Haase W, Bandelow B, Adler L, Ruther E (1995a): Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. European Psychiatry 10:S173-S179.

Hajak G, Clarenbach P, Fischer W, Rodenbeck A, Bandelow B, Broocks A, Ruther E (1998): Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci 248:148-56.

Hajak G, Rodenbeck A, Adler L, Huether G, Bandelow B, Herrendorf G, Staedt J, Ruther E (1996a): Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 29:187-92.

Hajak G, Rodenbeck A, Bandelow B, Friedrichs S, Huether G, Ruther E (1996b): Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects. Eur Neuropsychopharmacol 6:149-53.

Hajak G, Rodenbeck A, Herrendorf G, Staedt J, Bandelow B, Huether G, Rüther E (199?): Reduced nocturnal melatonin plasma concentration in patients with chronic primary insomnia. Pineal Res in press.

Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Ruther E (1995b): Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res 19:116-22.

Haug BA, Hermsteiner EM, Bandelow B, Paulus W (1997): Parallel increase of heterochromatic increment threshold and postadaptation thresholds in Parkinson's disease in neuroleptic treatment. Vision-Research 37:3535-3547.

Heindl S, Binder C, Desel H, Matthies U, Lojewski I, Bandelow B, Kahl GF, Chemnitius JM (2000): [Etiology of initially unexplained confusion of excitability in deadly nightshade poisoning with suicidal intent. Symptoms, differential diagnosis, toxicology and physostigmine therapy of anticholinergic syndrome]. Dtsch Med Wochenschr 125:1361-5.

Hohoff C, Jung A, Freitag CM, Willis-Owen SA, Ponath G, Krakowitzky P, Fritze J, Bandelow B, Franke P, Fimmers R, Nothen MM, Flint J, Deckert J (2005): Investigation of RGS2 and RGS13 gene polymorphisms in human panic disorder. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 138B:11-11.

Hohoff C, Mullings EL, Heatherley SV, et al (2010): Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality. J Psychiatr Res 44:930-7.

Hohoff C, Neumann A, Domschke K, Jacob C, Maier W, Fritze J, Bandelow B, Krakowitzky P, Rothermundt M, Arolt V, Deckert J (2008): Association analysis of Rgs7 variants with panic disorder. J Neural Transm.

Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B (2009): Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 24:87-96.

Keck ME, Kern N, Erhardt A, et al (2008): Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet 147B:1196-204.

Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I (2005): Randomized, double blind study of SR142801 (onasetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 38:24-29.

Leygraf A, Hohoff C, Freitag C, Willis-Owen SA, Krakowitzky P, Fritze J, Franke P, Bandelow B, Fimmers R, Flint J, Deckert J (2006): Rgs 2 gene polymorphisms as modulators of anxiety in humans? J Neural Transm 113:1921-5.

Link S, Paulus W, Bandelow B (2009): Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine. Mov Disord 24:2431-2.

Margraf J, Bandelow B (1997): Recommendations on assessment instruments for clinical research. Zeitschrift-Fur-Klinische-Psychologie-Forschung-Und-Praxis 26:150-156.

Meyer T, Broocks A, Bandelow B, Hillmer-Vogel U, Ruther E (1998): Endurance training in panic patients: spiroergometric and clinical effects. Int J Sports Med 19:496-502.

Möller HJ, Brasser M, Kasper S, Volz HP, Boerner RJ, Bandelow B (2009): Wirksamkeit und Verträglichkeit von Pregabalin bei Patienten mit generalisierten Angststörungen in der täglichen Praxis. Psychopharmakotherapie 16:211-217.

Möller HJ, Müller WE, Bandelow B (2000): Neuroleptika. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

Muller P, Bandelow B, Gaebel W, Kopcke W, Linden M, Muller-Spahn F, Pietzcker A, Schaefer E, Tegeler J (1992): Intermittent medication, coping and psychotherapy. Interactions in relapse prevention and course modification. Br J Psychiatry Suppl:140-4.

Muller P, Gaebel W, Bandelow B, Kopcke W, Linden M, Muller-Spahn F, Pietzcker A, Tegeler J (1998): [The social status of schizophrenic patients]. Nervenarzt 69:204-9.

Munzel U, Bandelow B (1998): The use of parametric vs. nonparametric tests in the statistical evaluation of rating scales. Pharmacopsychiatry 31:222-4.

Naber D, Bandelow B, Bender S, Klimke A, Kuhn K, Lambert M, Lemmer W, Riedel M, Vorbach E, Dittmann RW (2001): Subjective well-being under neuroleptic treatment with olanzapine versus clozapine: First results from a double-blind clinical trial using the SWN self-rating scale. Schizophrenia Research 49:240-240.

Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW (2005): Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 111:106-15.

Papakostas G, Bandelow B, Demyttenaere K, Trivedi M, Earley W, Szamosi J, Eriksson H (2010): Efficacy of extended release quetiapine fumarate (quetiapine XR) monotherapy on sleep disturbance in patients with major depressive disorder. International Journal of Neuropsychopharmacology 13:159-159.

Pauls J, Bandelow B, Ruther E, Kornhuber J (2000): Polymorphism of the gene of angiotensin converting enzyme: lack of association with mood disorder. J Neural Transm 107:1361-6.

Paulus W, Hermsteiner E, Haug B, Bandelow B (1995): Increment Threshold and Postadaptation Threshold Are Increased in Parkinsons-Disease. Investigative Ophthalmology & Visual Science 36:S227-S227.

Peter H, Bandelow B, Krausz M (1998a): Impact of the central serotonergic system on alcoholism and pharmacotherapeutic consequences. Fortschritte Der Neurologie Psychiatrie 66:459-465.

Peter H, Bandelow B, Krausz M (1998b): [The impact of the central serotonin system on alcoholism and therapeutic consequences]. Fortschr Neurol Psychiatr 66:459-65.

Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, Nutt DJ, Okasha A, Swinson RP (2003): WCA recommendations for the long-term treatment of panic disorder. Cns Spectrums 8:17-30.

Sandmann J, Lorch B, Bandelow B, Hartter S, Winter P, Hiemke C, Benkert O (1998): Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 31:117-21.

Sehmer-Kurz K, Stiens G, Bandelow B (2006): Therapie der Depression und Angst im Alter. Der Neurologe und Psychiater:31-38.

Simen S, Hajak G, Schlaf G, Westenhofer J, Rodenbeck A, Bandelow B, Pudel V, Ruther E (1995a): Chronic Sleep Complaints - Results of a Representative Survey in Germany. Nervenarzt 66:686-695.

Simen S, Hajak G, Schlaf G, Westenhofer J, Rodenbeck A, Bandelow B, Pudel V, Ruther E (1995b): [Chronification of sleep disorders. Results of a representative survey in West Germany]. Nervenarzt 66:686-95.

Stein DJ, Baldwin DS, Bandelow B, Blanco C, Fontenelle LF, Lee S, Matsunaga H, Osser D, Stein MB, van Ameringen M (2010): A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep 12:471-7.

Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B (2006): Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 67:1741-6.

Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B (2007a): More on placebo response - Reply. Journal of Clinical Psychiatry 68:1984-1985.

Stein DJ, Bandelow B (2004): Future Directions. In Bandelow B, Stein DJ (eds), Social Anxiety Disorder. New York: Marcel Dekker, pp 335-344.

Stein DJ, Bandelow B, Dolberg OT, Andersen HF, Baldwin DS (2008): How are symptom severity and functional recovery/relapse related? An analysis of the escitalopram database. European Psychiatry 23:S369-S369.

Stein DJ, Bandelow B, Dolberg OT, Andersen HF, Baldwin DS (2009): Anxiety symptom severity and functional recovery or relapse. Ann Clin Psychiatry 21:81-8.

Stein DJ, Bandelow B, Hollander E, Nutt DJ, Okasha A, Pollack MH, Swinson RP, Zohar J (2003): WCA Recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr 8:31-9.

Stein DJ, Ipser JC, Baldwin DS, Bandelow B (2007b): Treatment of obsessive-compulsive disorder. CNS Spectr 12:28-35.

Stubner S, Grohmann R, Engel R, Bandelow B, Ludwig WD, Wagner G, Muller-Oerlinghausen B, Moller HJ, Hippius H, Ruther E (2004): Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 37 Suppl 1:S70-8.

Tural U, Fidane H, Alkin T, Bandelow B (2002): Assessing the severity of panic disorder and agoraphobia: validity, reliability and objectivity of the Turkish translation of the Panic and Agoraphobia Scale (P&A). J Anxiety Disord 16:331-40.

Van Ameringen M, Allgulander C, Bandelow B, Greist JH, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP (2003): WCA recommendations for the long-term treatment of social phobia. CNS Spectr 8:40-52.

Völker S, Knopp G, Trampe A, Bandelow B, Hanemann B, Haag-Kirchner P, Fless F (2009): Idole: Annäherung an einen vagen Begriff. ISBN 978-3938832516. München: Edition Minerva.

Wedekind D, Bandelow B (2004): [Anxiety-ridden patients in the doctor's office]. MMW Fortschr Med 146:24-6.

Wedekind D, Bandelow B (2005): [The alpha2delta subunit of the voltage-dependent calcium channel. A new pharmaceutical target for psychiatry and neurology]. Nervenarzt 76:888-91.

Wedekind D, Bandelow B (2009): QUISS - Quantifizierungs-Inventar für Somatoforme Syndrome. Manual. Göttingen: Hogrefe.

Wedekind D, Bandelow B, Broocks A, Hajak G, Ruther E (2000): Salivary, total plasma and plasma free cortisol in panic disorder. J Neural Transm 107:831-7.

Wedekind D, Bandelow B, Fentzahn E, Trumper P, Ruther E (2007a): The quantification inventory for somatoform syndromes (QUISS): a novel instrument for the assessment of severity. Eur Arch Psychiatry Clin Neurosci 257:153-63.

Wedekind D, Bandelow B, Ruther E (2005): [Pharmacotherapy in personality disorders]. Fortschr Neurol Psychiatr 73:259-67.

Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B (2010a): A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry 11:904-13.

Wedekind D, Broocks A, Weiss N, Rotter-Glattkowski P, Engel K, Neubert K, Bandelow B (2007b): Controlled study for effectiveness of sport vs. relaxation training in combination with paroxetine vs. Placebo in the treatment of the panic disorder. Nervenarzt 78:510-510.

Wedekind D, Engel K, Bandelow B (2007c): [Early detection of anxiety disorders]. MMW Fortschr Med 149:32-5.

Wedekind D, Engel K, Bandelow B (2008a): [Social anxiety disorder--diagnostics and treatment options]. Fortschr Neurol Psychiatr 76:616-20; quiz 621-4.

Wedekind D, Herchenhein T, Kirchhainer J, Bandelow B, Falkai P, Engel K, Malchow B, Havemann-Reinecke U (2010b): Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion. J Psychiatr Res 44:1163-9.

Wedekind D, Herchenhein T, Kirchhainer S, Bandelow B, Engel K, Malchow B, Falkai P, Havermann-Reinecke U (2008b): Serotonergic function, substance craving, and psychopathology in detoxified alcohol addicted males undergoing tryptophane depletion. International Journal of Neuropsychopharmacology 11:241-241.

Wedekind D, Sprute A, Broocks A, Huther G, Engel K, Falkai P, Bandelow B (2008c): Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder. Curr Pharm Des 14:3518-24.

Wiltfang J, Schenk-Dapra B, Stiens G, Bleich S, Bandelow B, Muller P, Niedmann PD, Armstrong VW, Ruther E (2001): Clozapine-associated elevation of plasma cholinesterase. Eur Arch Psychiatry Clin Neurosci 251:269-71.

Wittchen HU, Linden M, Schwarzer W, Riemann D, Boerner RJ, Bandelow B (2001a): Generalisierte Angststörung. Fortschr Med Orig 119 Suppl 1:1-4.

Wittchen HU, Linden M, Schwarzer W, Riemann D, Boerner RJ, Bandelow B (2001b): Generalized anxiety disorders - A neglected illness? Background and aims of the GAD-P-Study. Mmw-Fortschritte Der Medizin:1-4.

Wobrock T, Bandelow B, Reinecke UH, Wedekind D (2010): Update psychiatry - alcohol addiction anxiety disorders major-depressive disorder schizophrenia. Nervenheilkunde 29:734-+.

Wolff-Menzler C, Bandelow B (2010): [The weeping patient]. MMW Fortschr Med 152:29-30.